{"name":"Mankind Pharma","slug":"mankind-pharma","ticker":"MANKIND.NS","exchange":"NSE","domain":"mankindpharma.com","description":"Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.","hq":"New Delhi, India","founded":1991,"employees":"19620","ceo":"Rajeev Juneja (Vice Chairman & MD)","sector":"Consumer Health / Branded Generics","stockPrice":2462.2,"stockChange":54.6,"stockChangePercent":2.27,"marketCap":"$10.6B","metrics":{"revenue":1453015848.3786957,"revenueGrowth":10.4,"grossMargin":70.2,"rdSpend":0,"netIncome":186266719.23645645,"cash":365349825.8339676,"dividendYield":8,"peRatio":57.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-30","label":"SITAGLIPTIN AND METFORMIN HCL Phase 3 readout (Type 2 Diabetes (Adult Onset))","drug":"SITAGLIPTIN AND METFORMIN HCL","drugSlug":"sitagliptin-metformin-hydrochloride","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Manforce patent cliff ($100MB at risk)","drug":"Manforce","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SITAGLIPTIN AND METFORMIN HCL","genericName":"SITAGLIPTIN, METFORMIN HYDROCHLORIDE","slug":"sitagliptin-metformin-hydrochloride","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"SITAGLIPTIN AND METFORMIN HCL","genericName":"SITAGLIPTIN, METFORMIN HYDROCHLORIDE","slug":"sitagliptin-metformin-hydrochloride","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Mankind Pharma reports 15% YoY growth in Q4 FY2024","summary":"The company's revenue grew to ₹1,234 crore in Q4 FY2024, driven by strong sales of its branded generics and consumer health products.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"deal","headline":"Mankind Pharma partners with US-based company for distribution of its products","summary":"The partnership aims to expand Mankind Pharma's presence in the US market and increase its distribution network.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQaXlGdUt1bUNRV0hRX3hOQ2dmd0lUTjhJZkszSFJ2RFoxYW1GZ3RuVWE5bm8zZTQtSFp4V2k1OHBoTkhEUjVMSDQ1bXcyRzl4MkZFcnllRzg1dzU1UDNWYVRUWVdEMXJDaENSNE9vVW94RjBpX3duczFTenM3SWxwOUFob05SZw?oc=5","date":"2026-02-23","type":"pipeline","source":"Yahoo Finance UK","summary":"Condom Market Report 2026-2035: A $22.57 Billion Industry by 2030 with Reckitt Benckiser, Church & Dwight, Humanwell Healthcare, Okamoto Industries, Mankind Pharma, Karex Berhad Leading - Yahoo Financ","headline":"Condom Market Report 2026-2035: A $22.57 Billion Industry by 2030 with Reckitt Benckiser, Church & Dwight, Humanwell Hea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNGt4MkczNmhycTRYUWVaVVctc2kyMi1kWmJ1Z2pRRW94cml3anZncG14RTBJV3ZkTXBpWTVQdWlnci1GM090YUpUd3Z5aEVzaVN5QmtabEdMR1cwclBSbWJaR0s0dktzN2htZGM5WUo4SmpCclVzYXowVnU3V3lhQzZqMUtZOERzZjJNVlpZWnZCYjBLcEh0eGlkMjdSNFIxdXkxQUdRamFxUUFGM013NFFnLTJaTlR6a3VNVjNXaU1QVU1ZcU9lZ19oREJ2OGhJOGVVZlAwZkhxaU02ZWhjbUJ3?oc=5","date":"2026-02-03","type":"regulatory","source":"Reuters","summary":"Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand - Reuters","headline":"Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNOWxJRVhKT0pfb2RIMEMxNFBFUk92VXJWM3htSHhOd25IMDl6SVpSUG0xYTJTeHRxdXB1WHliNVkxNnFwbjJ4bVlFRVdkcmRHYTV3YmJCUnVtN2dyUWtZekl0MVFJdEFmUlh6N2NmQndsNkRQRTdPZFdkWU8yY1h0QkJFNGdIbTBLbUdZM1N5VQ?oc=5","date":"2026-02-03","type":"regulatory","source":"Yahoo Finance Singapore","summary":"Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand - Yahoo Finance Singapore","headline":"Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOSXR2UXVsTXlObDJqWEFmdjluMG5VTkNXSHNhaTR3UHgyUU4ybHUydno3Z2txazJGS2xTaTQzeVI5QXZJWUNhSnpycGhwXzZjYllGcTNJeW5Qdmp4dUJYbDdFTDkxMzBVQ001MGxTV3ZaZktWSGJXb0x1c3VlbEtKM3RHbEdpRFZUMmRVR0hfTmRaT1J4dFFlWXNEaHpDMWI3UUYtTlZNYVVXWWNvU2NYTjlpY3RuQzdCY3dzeXpFM1RLWmtZUUhSemlLemh6d3NERy1Yb1hja3g4bVMwdWJkN0lYUQ?oc=5","date":"2025-11-06","type":"earnings","source":"Reuters","summary":"Mankind Pharma posts fourth straight quarterly profit fall on sales hit from tax cuts - Reuters","headline":"Mankind Pharma posts fourth straight quarterly profit fall on sales hit from tax cuts","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQUURrV0dZaTVwM2xhMWZTTUxfX1F4bklvSmF3WGU1QXJzakJva2JiSE95R2x1QjBTUWV4UGx2cjkybWVtTmxCMENNQ0RDRjBweURGeXVFSmk2Q3o4QVFYdmItZTJNMFlEeWtqb0VxaEZTbDZSOFZvWEx6Mktjc2pLeDV4R1pwOUF5R0E?oc=5","date":"2025-11-06","type":"earnings","source":"Yahoo Finance","summary":"Mankind Pharma posts fourth straight quarterly profit fall on sales hit from tax cuts - Yahoo Finance","headline":"Mankind Pharma posts fourth straight quarterly profit fall on sales hit from tax cuts","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOZVJscFQ1RGJlYlJPelBRc1p0NnVHRFUxQWxudm1nWDJ3d0NxUWNvcU5uUDBnNm1PYTFXdUhyd1plTHBrYlVuc1VqdDZBdWxTMWlQRGZzRHpNcHljbEVNNG55Z2xhLWxLeEhnUUFEOEd2RzNNeWE2RHR4ay13Y2R5Z0JFMmI5bzhPVEE?oc=5","date":"2025-07-31","type":"earnings","source":"Yahoo Finance Singapore","summary":"India's Mankind Pharma posts lower quarterly profit as costs surge - Yahoo Finance Singapore","headline":"India's Mankind Pharma posts lower quarterly profit as costs surge","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOZ0VMS3pKeFM5b25kZHluQ1VjNTFVc0JYUVM2NjF3ZG5WNjkwUFg5TFdOQjBPNHdkdzBNNHRjWVVDcFdFcmRTSlZFY0pLM2FWZWZyZzU3N0NHRHFlYzZncmZKbF9HajRlNTRFeXItVl9mN09FWmZib21VLUpiNUNzaG5TSzZoTkVLZ3VHMW1sWjJ1ZWMtMkJiVzdabHVwS1BCbkYyeTZ2dGMydkstS0YtTGVzTWRDb292YVNDTGc0NUY5cVdDWjhNTjlxYlluVktrR2MtbGZYZlhyY00?oc=5","date":"2025-05-21","type":"regulatory","source":"Reuters","summary":"India's Mankind Pharma beats profit estimates on demand for drugs to treat chronic illnesses - Reuters","headline":"India's Mankind Pharma beats profit estimates on demand for drugs to treat chronic illnesses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPQVRWVXRBQjRsMXVxaGdidnI0dVVDRWJSazA5UktqT2tuRk05NjhVeUtuN3o4eHc0emVKdlhfTVVEQnp1WDNYN2JXbVZza3IzOXVrODZ2Uk5Lcm9kajFJNXJZTTY4MFhVbTBvb1hqZDhKR1BET1JRYnQ5OHM5bG85dGRaNlBNVXBMUVlBZ1B2dFgyMGtCbTZPLTNOZE55Nkt6UXdfVzJZdXFaQ0hPUUtUWGQwTFRqREM2Q2JWaGlZODBQb2kwR2xBaA?oc=5","date":"2025-01-23","type":"earnings","source":"Reuters","summary":"India's Mankind Pharma misses Q3 profit view as expenses jump - Reuters","headline":"India's Mankind Pharma misses Q3 profit view as expenses jump","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPUG1PUVNIb3VQVGNkRlMyUC1BUGkxNkk1MTlqTFZoMTJzb0tiWkdYa2c3Y0loWDhwd1dWZGwwVkxUT2g1aU0xSmdMUExoY0w0VGYwRzA0SE1VOG1iR2I5NTEtNUh4N3dwS0ZqVV9TT2VSVy1jOWZ6TTQxa1dtdTkyTkxOcUFULTV4Y3JmYV9Ea25SbFF6TjdVSDlGR0xZWVNnT0Vhb1NfVXhCWTBvWEFkczFqV3BlbXdzc1JJMlBYV0pOYlhDVlE0TUtTczlLTENBMXc?oc=5","date":"2024-07-31","type":"earnings","source":"Reuters","summary":"India's Mankind Pharma misses Q1 profit expectations on higher costs - Reuters","headline":"India's Mankind Pharma misses Q1 profit expectations on higher costs","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNbVdZQlpQcDloWnlpVHNoV0UtZkl6MjlVSVZycXIxT2tyZzJ2eFJMWDRLRWh1TXI3Q1Q1c2hRY0Vjakw4Zmh4MXl1R0JSSWJIQnFhT0ZULWx3NXF3ZlF5NHNsYlJwWktSbDV6Y2U1Y2VCUmFDejJ3ZU1hdl91bjQxVmZjTVhmNGprTW5TU0RzRG9TODZ4NkxtbXZzN0VyQlJpMTUwREx0V0dramN5ZDJFZkhrUmcyQnVaZ3JHVFFRTzF3elBQWk50Tk80dGloSlR6Q1lzYnlUNXg?oc=5","date":"2024-05-15","type":"earnings","source":"Reuters","summary":"India's Mankind Pharma's Q4 profit jumps on strength in chronic drugs segment - Reuters","headline":"India's Mankind Pharma's Q4 profit jumps on strength in chronic drugs segment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1pNmFsNDlEalRZRFJkWjNNVEFYT3FWa0tkeXZTS08tVDZVWXU5OHp2WFdHbmtaeFBRX1A4WE81aWFWZTQ4b0ZDUUZlT0lnVE5LMjJ5a3NMWmNTRU0yVGc?oc=5","date":"2024-03-19","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Concord Biotech Limited (CONCORDBIO.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Concord Biotech Limited (CONCORDBIO.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNbzMwZzlFeUd6OUx5bFFqX1VFUGZRUkVjS3FZOXI1SUxyd001RzJIOGJyNEFyTGZzSVVXcm9wVUFMTjRHRzZYZ1NMYWxLYVFrbm1BLWJrZ2t5NFY1Q09yTUZqaEFQM2VuTERlWmhiaVJtM1VUdnp1bWpzald3TVVMb05oZ3FEbkg4NXYwNHFwSERnVjVyemZGc1M4ZXlVNEFzY2d6RFpwZWI2YWEwVDRFSGc3ZERaUzZsV1JSRl9NdGE3N0xta1B4YWgtbWlIYUxDR0c1eFJUVEtMZWY4WFE?oc=5","date":"2023-05-30","type":"earnings","source":"Reuters","summary":"India's Mankind Pharma posts 43% jump in Q4 profit in first results since listing - Reuters","headline":"India's Mankind Pharma posts 43% jump in Q4 profit in first results since listing","sentiment":"neutral"}],"patents":[{"drugName":"Manforce","drugSlug":"sildenafil","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Cipla","Sun Pharma","Aurobindo Pharma"],"therapeuticFocus":["Dermatology","Gastroenterology","Pain Management"],"financials":{"source":"yahoo_finance","revenue":1274795370.3856,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":1274795370.3856},{"period":"2024-03-31","value":1071354468.7046},{"period":"2023-03-31","value":913683514.47142},{"period":"2022-03-31","value":812610202.3357}],"grossProfit":902073969.3324,"grossProfitHistory":[{"period":"2025-03-31","value":902073969.3324},{"period":"2024-03-31","value":731200946.9252},{"period":"2023-03-31","value":604334390.277666},{"period":"2022-03-31","value":554672849.11378}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":144151008.01860002,"operatingIncome":262722441.12420002,"operatingIncomeHistory":[{"period":"2025-03-31","value":262722441.12420002},{"period":"2024-03-31","value":233841905.3498},{"period":"2023-03-31","value":171430290.598936},{"period":"2022-03-31","value":196703641.60716}],"netIncome":207911453.2304,"netIncomeHistory":[{"period":"2025-03-31","value":207911453.2304},{"period":"2024-03-31","value":199759823.84600002},{"period":"2023-03-31","value":133861648.811434},{"period":"2022-03-31","value":149694554.5965}],"eps":49.2,"epsHistory":[{"period":"2025-03-31","value":49.2},{"period":"2024-03-31","value":47.68},{"period":"2023-03-31","value":31.999403},{"period":"2022-03-31","value":35.784233}],"cash":42539684.1664,"cashHistory":[{"period":"2025-03-31","value":42539684.1664},{"period":"2024-03-31","value":39892440.9574},{"period":"2023-03-31","value":31831736.806218002},{"period":"2022-03-31","value":31592941.89316}],"totalAssets":2898864981.3622003,"totalLiabilities":1377542868.049,"totalDebt":888831487.623,"equity":1496699096.4986,"operatingCashflow":252023819.16120002,"operatingCashflowHistory":[{"period":"2025-03-31","value":252023819.16120002},{"period":"2024-03-31","value":224774444.6856},{"period":"2023-03-31","value":189358998.469158},{"period":"2022-03-31","value":96050128.98624}],"capex":-55426067.2824,"capexHistory":[{"period":"2025-03-31","value":-55426067.2824},{"period":"2024-03-31","value":-40644320.6854},{"period":"2023-03-31","value":-86891085.19406},{"period":"2022-03-31","value":-244937666.00802}],"freeCashflow":196597751.8788,"dividendsPaid":0,"buybacks":null,"employees":19620,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":69569760.388,"ebitda":92815375.312,"period":"2025-12-31","revenue":372514634.128,"epsBasic":9.9,"netIncome":42684838.725,"rdExpense":null,"epsDiluted":9.89,"grossProfit":270385348.6854,"operatingIncome":72768382.0642},{"sga":null,"ebit":74262743.0236,"ebitda":97099001.2068,"period":"2025-06-30","revenue":372843581.509,"epsBasic":10.62,"netIncome":45772766.9968,"rdExpense":null,"epsDiluted":10.6,"grossProfit":262819558.9224,"operatingIncome":65590019.2166},{"sga":null,"ebit":71429618.4374,"ebitda":93940062.07180001,"period":"2025-03-31","revenue":314067472.3274,"epsBasic":null,"netIncome":43940060.1598,"rdExpense":null,"epsDiluted":null,"grossProfit":215222439.3078,"operatingIncome":58468047.3486},{"sga":null,"ebit":74066418.8724,"ebitda":93612158.9682,"period":"2024-12-31","revenue":334042410.4346,"epsBasic":9.45,"netIncome":39706559.5802,"rdExpense":null,"epsDiluted":9.44,"grossProfit":236766926.3472,"operatingIncome":65666251.466800004},{"sga":null,"ebit":89633462.0742,"ebitda":100127405.6668,"period":"2024-09-30","revenue":319698216.0682,"epsBasic":16.31,"netIncome":68240395.2578,"rdExpense":null,"epsDiluted":16.28,"grossProfit":228562038.8154,"operatingIncome":77976193.458}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2462.2,"previousClose":2407.6,"fiftyTwoWeekHigh":2716.5,"fiftyTwoWeekLow":1909.7,"fiftyTwoWeekRange":"1909.7 - 2716.5","fiftyDayAverage":2161.06,"twoHundredDayAverage":2279,"beta":0.47,"enterpriseValue":10914523674.848396,"forwardPE":41.3,"priceToBook":6.65,"priceToSales":7.31,"enterpriseToRevenue":7.51,"enterpriseToEbitda":32.33,"pegRatio":0,"ebitda":337622458.35763305,"ebitdaMargin":23.2,"freeCashflow":0,"operatingCashflow":0,"totalDebt":873919188.6400553,"debtToEquity":53.9,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":20,"targetMeanPrice":2543.45,"targetHighPrice":3100,"targetLowPrice":1990,"dividendRate":2,"payoutRatio":0.02,"fiveYearAvgDividendYield":0,"exDividendDate":1754611200,"insiderHeldPercent":75.3,"institutionHeldPercent":18.4,"sharesOutstanding":412828328,"floatShares":112839772,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":43.1,"epsForward":59.63,"revenuePerShare":337.46,"bookValue":370.26,"officers":[{"age":70,"name":"Mr. Ramesh C. Juneja","title":"Whole-Time Director & Executive Chairman"},{"age":50,"name":"Mr. Sheetal  Arora","title":"CEO & Whole-Time Director"},{"age":60,"name":"Mr. Rajeev  Juneja","title":"Vice Chairman & MD"},{"age":52,"name":"Mr. Satish Kumar Sharma","title":"Whole-Time Director"},{"age":57,"name":"Mr. Ashutosh  Dhawan MBA","title":"Chief Financial Officer"},{"age":39,"name":"Mr. Arjun  Juneja","title":"Chief Operating Officer"},{"age":null,"name":"Mr. Chanakya  Juneja","title":"Director of Technology"},{"age":54,"name":"Mr. Pramod  Gokhale","title":"Senior President & Group Chief Information Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.mankindpharma.com","phone":"91 11 4684 6700"}}